Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS) announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL.
Event format: fireside chat and one-on-one meetings. Date and time: December 3, 2025 at 1:45 PM ET. A webcast replay will be available on the company’s investor events page at https://ir.fractyl.com/.
Positive
- None.
Negative
- None.
News Market Reaction – GUTS
In the Dec 1 session, GUTS declined 0.64%, reflecting a mild negative market reaction. Argus tracked a peak move of +25.2% during that session. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.2x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Clinical results | Positive | +17.9% | Positive 6‑month REVEAL‑1 results with sustained weight maintenance data. |
| Dec 01 | Conference participation | Neutral | -0.6% | Announcement of participation in Evercore healthcare investor conference. |
| Nov 12 | Earnings and update | Positive | +2.7% | Q3 2025 results with Revita/Rejuva progress and cash runway into 2027. |
| Nov 05 | Earnings scheduling | Neutral | +0.9% | Scheduling of Q3 2025 results call and webcast details. |
| Oct 07 | Preclinical data | Positive | -6.8% | Potent RJVA‑002 preclinical obesity data in a mouse model. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions to major clinical readouts, modest moves around earnings and routine events, and one notable selloff on preclinical data.
Over the last six months, Fractyl Health has reported several key milestones. Positive REVEAL‑1 data on Dec 02, 2025 coincided with the strongest move, while potent RJVA‑002 preclinical results on Oct 07, 2025 saw a negative reaction. Q3 2025 results on Nov 12, 2025 highlighted clinical momentum and extended cash runway. Routine items such as conference participation on Dec 01, 2025 and earnings call scheduling on Nov 05, 2025 drew only modest price changes. Today’s conference-related news fits this pattern of limited impact versus clinical catalysts.
Key Terms
type 2 diabetes medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.
8th Annual Evercore Conference
Format: Fireside chat and one-on-one meetings
Date: 12/03/2025
Time: 1:45 PM ET
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 45 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
